Infliximab Product Approval Information - Licensing Action

Proper name: Infliximab
Tradename: Remicade
Manufacturer: Centocor, Inc, Malvern, PA, License #1242
Indication for Use: Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s)
Approval Date: 8/24/98
Type of submission: Biologics license application


Approval Letter (PDF)

Label (PDF)

Review Documents
      Clinical Review (CBER) (PDF)
      Clinical Review (CDRH) (PDF)
      Clinical Pharmacology (PDF)
      Pharmacology Review (PDF)
      Product Review (PDF)
      Product Review (Attachments 1-8) (PDF)
      Statistical Review (PDF)

Page Last Updated: 05/16/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English